Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
irradiation for patients with small-cell lungcancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med . 1999 ; 341 : 476–484 | | | In ES disease, treatment typically involves chemotherapy alone x 9 Green, R.A., Humphrey, E., Close, H., and Patno, M.E. Alkylating agents in bronchogenic carcinoma. Am J Med . 1969 ; 46 : 516–525 | | | with or without PCI. x 10 Slotman, B., Faivre-Finn, C., Kramer, G. et al. Prophylactic cranial irradiation in extensive small (...) will commission a replacement or reaffirmation within 5-years of publication. 1. Introduction Small cell lungcancer (SCLC) is the second most common thoracic malignancy, representing approximately 13% of newly diagnosed lungcancers. x 1 in: N. Howlader, A. Noone, M. Krapcho, (Eds.) SEER Cancer Statistics Review . National Cancer Institute , Bethesda, MD ; 1975-2016 ( Available at: ) . ( Accessed November 22, 2019 ) SCLC is a particularly aggressive malignancy, with only about one-third of patients diagnosed
When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lungcancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lungcancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) chemotherapy for patients with mesothelioma to those with epithelioid tumours. 4. Information for Patients Please discuss with all patients undergoing diagnostic and staging tests or being referred for treatment that there are intense pressures on the NHS which may result in longer waits to undergo tests, see specialist clinicians and commence treatment. Please ensure they have contact details of their lungcancer specialist nurses (LCNS) or relevant team to discuss any concerns and seek support
EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lungcancer. It helps early detection of lungcancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lungcancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lungcancer recommends sputum cytology for investigation in people with suspected lungcancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided
: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lungcancer. However, nonsmokers with lungcancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lungcancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest
(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib
Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lungcancer: a randomized clinical trial Pain management makes an important contribution to good respiratory care and early recovery after thoracic surgery. Although the development of video-assisted thoracoscopic surgery (VATS) has led to improved patient outcomes, chest tube removal could be distressful experience for many patients. The aim of this trial was to test whether (...) the addition of lidocaine cream would have a signiﬁcant impact on the pain treatment during chest tube removal from patients who had undergone VATS for lung cancer.This clinical trial was a double-blind randomized study. Forty patients with histologically confirmed lungcancer amenable to lobectomy/segmentectomy were enrolled. All patients had standard perioperative care. Patients were randomly assigned to receive either epidural anesthesia plus placebo cream (placebo, Group P) or epidural anesthesia plus
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell LungCancer RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lungcancer (NSCLC).The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point (...) survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment
LungCancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lungcancer (NSCLC) and SCLC.ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature (...) for this guideline.Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lungcancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. There are limited data from randomized trials regarding whether volume-based, low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among male former and current smokers.A total of 13,195 men (primary analysis) and 2594 women (subgroup analyses) between the ages of 50 and 74 were randomly assigned to undergo CT screening at T0 (baseline), year 1, year 3, and year 5.5 or no screening. We (...) obtained data on cancer diagnosis and the date and cause of death through linkages with national registries in the Netherlands and Belgium, and a review committee confirmed lungcancer as the cause of death when possible. A minimum follow-up of 10 years until December 31, 2015, was completed for all participants.Among men, the average adherence to CT screening was 90.0%. On average, 9.2% of the screened participants underwent at least one additional CT scan (initially indeterminate). The overall
,EasternCooperativeOncologyGroup; EGFR,epidermalgrowthfactorreceptor;IHC,immunohistochemistry;N/A, notapplicable;NSCLC, non–small-cell lungcancer; PD-L1, programmed death ligand 1; PS, performance status; SCC, squamous cell carcinoma; Teff, T effector; TPS, tumor proportion score. Journal of Clinical Oncology 7 Systemic Therapy for Stage IV NSCLC Guideline UpdatePatients with cancers with sensitizing EGFR or ALK alter- ations were excluded from the trial. The study’s primary outcomeswereOSandPFS.OSintheinterventionarmwas (...) Therapy for Stage IV Non–Small-Cell LungCancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD
Guideline Update Guideline Question What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lungcancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer? Target Population Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) (with known EGFR and ALK ) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results (...) Therapy for Stage IV Non-Small Cell LungCancer without Driver Alterations Therapy for Stage IV Non–Small-Cell LungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non